Uses
NAFTIN ® Gel is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
Source: US FDA prescribing information
Naftifine is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. It is available as cream and gel for topical use. MedsAcross supplies Naftifine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NAFTIN ® Gel is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
Source: US FDA prescribing information
NAFTIN ® Gel is a topical antifungal drug.
Source: US FDA prescribing information
Apply a thin layer of NAFTIN ® Gel once daily to the affected areas plus an approximate ½ inch margin of healthy surrounding skin for 2 weeks. For topical use only. NAFTIN ® Gel is not for ophthalmic, oral, or intravaginal use. For topical use only.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
If redness or irritation develops with the use of NAFTIN ® Gel treatment should be discontinued. Local Adverse Reactions If irritation or sensitivity develops with the use of NAFTIN ® Gel, treatment should be discontinued.
Source: US FDA prescribing information
The most common adverse reactions are application site reactions (2%).
Source: US FDA prescribing information
Store NAFTIN ® Gel at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Naftifine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Naftifine 1% creamTopicalGeneric name | — | US FDA | Available on request |
| Naftifine 2% creamTopicalGeneric name | — | US FDA | Available on request |
| Naftifine 2% gelTopicalGeneric name | — | US FDA | Available on request |
| Naftin 2% gelTopical | Legacy Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 February 1988 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Naftifine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Naftifine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Naftifine, including Naftin.
Yes. The US FDA first approved Naftifine on 29 February 1988, according to Drugs@FDA.
No listed presentation of Naftifine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Naftifine is classified under ATC code D01AE22 (Naftifine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.